Bank of New York Mellon’s Greenwich LifeSciences GLSI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.12M Buy
47,900
+1,377
+3% +$33.5K ﹤0.01% 3291
2026
Q1
$1.12M Buy
46,523
+32,657
+236% +$852K ﹤0.01% 3141
2025
Q4
$291K Sell
13,866
-1,262
-8% -$13.3K ﹤0.01% 3877
2025
Q3
$151K Buy
15,128
+532
+4% +$6K ﹤0.01% 4067
2025
Q2
$132K Buy
14,596
+3,393
+30% +$32.3K ﹤0.01% 4042
2025
Q1
$107K Hold
11,203
﹤0.01% 3994
2024
Q4
$126K Hold
11,203
﹤0.01% 4011
2024
Q3
$161K Sell
11,203
-4,092
-27% -$60.6K ﹤0.01% 3952
2024
Q2
$264K Buy
+15,295
New +$223K ﹤0.01% 3865
2022
Q2
Sell
-10,114
Closed -$198K 4643
2022
Q1
$198K Hold
10,114
﹤0.01% 4244
2021
Q4
$246K Buy
10,114
+181
+2% +$6.06K ﹤0.01% 4179
2021
Q3
$388K Buy
9,933
+3,269
+49% +$137K ﹤0.01% 3944
2021
Q2
$300K Buy
+6,664
New +$252K ﹤0.01% 3970

Other funds holding GLSI

Bank of New York Mellon's GLSI Position: Q2 2026 in Review

Bank of New York Mellon increased its Greenwich LifeSciences (GLSI) stake by 3% in Q2 2026, buying an estimated $33.5K and bringing the position to 47,900 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3291.

Bank of New York Mellon first reported a position in GLSI in Q2 2021 and has held it in 13 quarters since. 24 funds tracked by Wall St. Rank hold GLSI as of Q2 2026.

  • Bank of New York Mellon held 47,900 shares of Greenwich LifeSciences worth $1.12M as of Q2 2026.
  • Bank of New York Mellon bought 1,377 Greenwich LifeSciences shares in Q2 2026, an estimated $33.5K.
  • Greenwich LifeSciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3291 holding.
  • Bank of New York Mellon first reported a position in Greenwich LifeSciences in Q2 2021 and has held it in 13 quarters since.
  • 24 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.